Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
Relapse risk and loss in expectation of lifetime in young classical hodgkin lymphoma patients

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.12.18
Views: 381

Dr Jorne Lionel Biccler - Aalborg University, Aalborg, Denmark

Dr Jonge Biccler speaks to ecancer at ASH 2018 about relapse risk and loss in expectation of lifetime in young classical hodgkin lymphoma patients.

He explains that up to date information is important not only for patients, but also for providing the backbone of rational follow up programs.

Dr Biccler says that one of the main implications is that a focus on detecting relapses in patients who are unlikely to have them is not very cost efficient, when instead those resources could be used towards late toxicities such as cardiovascular disease.

Watch his interview on CNS lymphoma here

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation